Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Krystal Biotech Inc (NQ: KRYS)
24.00 USD  -1.27 (-5.03%)
Official Closing Price  /  Updated: 4:00 PM EST, Jan 16, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 41,300
Open 24.98
Bid (Size) 23.50 (1)
Ask (Size) 24.98 (10)
Prev. Close 25.27
Today's Range 23.49 - 25.43
52wk Range 8.610 - 28.75
Shares Outstanding 10,309,615
Dividend Yield N/A
Performance
YTD
+5.08%
+5.08%
1 Month
+2.08%
+2.08%
3 Month
+12.10%
+12.10%
6 Month
+30.36%
+30.36%
1 Year
+143.16%
+143.16%
Top News
More News
Krystal Biotech Completes Construction of Ancoris - A New GMP Facility for Commercial Manufacturing of a Viral Vector-Based Gene Therapy to Treat Dystrophic Epidermolysis Bullosa
Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that... Read More
from GlobeNewswire News Releases
Krystal Biotech Completes Dosing in the GEM-Phase 2 Study in Pediatric Patients for the Treatment of Dystrophic Epidermolysis Bullosa
Top line results from GEM-Phase 2 study expected in H1 2019 Read More
from GlobeNewswire News Releases
More News
Read More
New Research Coverage Highlights VSE, Weyco Group, Funko, B. Riley Financial, Krystal Biotech, and Xcel Brands — Consolidated Revenues, Company Growth, and Expectations for 2018
from GlobeNewswire News Releases
Krystal Biotech to Present at Evercore ISI HealthCONx
from GlobeNewswire News Releases
Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update
from GlobeNewswire News Releases
Krystal Biotech Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Over-Allotment Option
from GlobeNewswire News Releases
Chardan Serves as Lead Manager for Krystal Biotech
from PR Newswire
Krystal Biotech Announces Pricing of $60.0 Million Public Offering of Common Stock
from GlobeNewswire News Releases
Krystal Biotech Announces Commencement of $60.0 Million Public Offering of Common Stock
from GlobeNewswire News Releases
Analysts Anticipate DWAS To Hit $54
category ETFs
from ETF Channel
Investors Land KRYS Even Lower Than Its Secondary Stock Offering
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.